Sarcopenia and cardiovascular disease in patients with and without kidney disease: what do we know?

被引:0
|
作者
Ozkan Gungor
Mustafa Sevinc
Sena Ulu
Ismail Kocyigit
机构
[1] Kahramanmaras Sutcu Imam University,Nephrology Department, Medical Faculty
[2] Bakirkoy Dr. Sadi Konuk Education and Research Hospital,Nephrology Department
[3] Bahcesehir University,Nephrology Department, Medical Faculty
[4] Erciyes University,Nephrology Department, Medical Faculty
来源
International Urology and Nephrology | 2023年 / 55卷
关键词
Sarcopenia; Cardiovascular disease; Kidney patients; Muscle; Kidney;
D O I
暂无
中图分类号
学科分类号
摘要
Cardiovascular disease (CVD) incidence is high in patients with chronic kidney disease (CKD) and is the most frequent cause of mortality in this population. Advanced age, hypertension, uremic toxins, endothelial dysfunction, atherosclerosis, hyperhomocysteinemia, oxidative stress, and inflammation are among the leading causes of increased CVD in advanced stages of CKD. Although defined as a decrease in muscle strength associated with aging, sarcopenia is also prevalent in CKD patients. Sarcopenia causes physical disability, low quality of life, and mortality. Regular exercise and nutritional supplementation may slow the progression of sarcopenia. Recent studies have shown that sarcopenia increases the risk of CVD and mortality in people with or without kidney disease. This review discusses the relationship between sarcopenia and CVD in light of the current literature.
引用
收藏
页码:1161 / 1171
页数:10
相关论文
共 50 条
  • [41] Diagnosis of Cardiovascular Disease in Patients with Chronic Kidney Disease
    McCullough, Peter A.
    Assad, Hadeel
    BLOOD PURIFICATION, 2012, 33 (1-3) : 112 - 118
  • [42] Diabetes, Cardiovascular Disease, and Cardiovascular Risk in Patients with Chronic Kidney Disease
    Jose J. G. De Lima
    Luis Henrique W. Gowdak
    Elias David-Neto
    Luiz A. Bortolotto
    High Blood Pressure & Cardiovascular Prevention, 2021, 28 : 159 - 165
  • [43] Nitrotyrosine, Nitrated Lipoproteins, and Cardiovascular Dysfunction in Patients with Type 2 Diabetes: What Do We Know and What Remains to Be Explained?
    Jakubiak, Grzegorz K.
    Cieslar, Grzegorz
    Stanek, Agata
    ANTIOXIDANTS, 2022, 11 (05)
  • [44] Chronic kidney disease in patients with non-alcoholic fatty liver disease: What the Hepatologist should know?
    Kiapidou, Stefania
    Liava, Christina
    Kalogirou, Maria
    Akriviadis, Evangelos
    Sinakos, Emmanouil
    ANNALS OF HEPATOLOGY, 2020, 19 (02) : 134 - 144
  • [45] Screening Tests for Sarcopenia in Patients with Chronic Kidney Disease
    Jiang, Keruo
    Slee, Adrian
    Davenport, Andrew
    NUTRITION IN CLINICAL PRACTICE, 2021, 36 (05) : 1049 - 1052
  • [46] Mitochondrial Dysfunction in Kidney Disease and Uremic Sarcopenia
    Takemura, Koji
    Nishi, Hiroshi
    Inagi, Reiko
    FRONTIERS IN PHYSIOLOGY, 2020, 11
  • [47] Cardiovascular Effects of COVID-19 - What Do We Know and Where Should We Go?
    Ryan, Matthew
    Demir, Ozan
    O'Gallagher, Kevin
    Perera, Divaka
    HEART INTERNATIONAL, 2020, 14 (01): : 16 - 19
  • [48] Extra-coronary Calcification and Cardiovascular Events: What Do We Know and Where Are We Heading?
    Dixitha Anugula
    Rhanderson Cardoso
    Gowtham R. Grandhi
    Ron Blankstein
    Khurram Nasir
    Mouaz Al-Mallah
    Dipan J. Shah
    Miguel Cainzos-Achirica
    Current Atherosclerosis Reports, 2022, 24 : 755 - 766
  • [49] Extra-coronary Calcification and Cardiovascular Events: What Do We Know and Where Are We Heading?
    Anugula, Dixitha
    Cardoso, Rhanderson
    Grandhi, Gowtham R.
    Blankstein, Ron
    Nasir, Khurram
    Al-Mallah, Mouaz
    Shah, Dipan J.
    Cainzos-Achirica, Miguel
    CURRENT ATHEROSCLEROSIS REPORTS, 2022, 24 (10) : 755 - 766
  • [50] Do patients with chronic kidney disease get optimal cardiovascular risk reduction?
    Elliott, Mark K.
    McCaughan, Jennifer A.
    Fogarty, Damian G.
    CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2014, 23 (03) : 267 - 274